Aprea Therapeutics, Inc. financial data

Symbol
APRE on Nasdaq
Location
Doylestown, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 12 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 591% % -25%
Return On Equity -88% % -52%
Return On Assets -69% % -43%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6,310,673 shares 16%
Common Stock, Shares, Outstanding 5,979,292 shares 10%
Entity Public Float $10,000,000 USD 0%
Common Stock, Value, Issued $5,979 USD 10%
Weighted Average Number of Shares Outstanding, Basic 6,372,938 shares 7.3%
Weighted Average Number of Shares Outstanding, Diluted 6,372,938 shares 7.3%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $5,911,745 USD -16%
Operating Income (Loss) $13,816,788 USD 6.4%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $13,038,738 USD 3.5%
Earnings Per Share, Basic -2 USD/shares 23%
Earnings Per Share, Diluted -2 USD/shares 20%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $13,718,052 USD -48%
Assets, Current $13,943,988 USD -47%
Property, Plant and Equipment, Net $65,236 USD -25%
Other Assets, Noncurrent $271,162 USD -3.7%
Assets $14,321,316 USD -47%
Accounts Payable, Current $641,322 USD -44%
Employee-related Liabilities, Current $588,789 USD -13%
Liabilities, Current $2,681,107 USD -26%
Accumulated Other Comprehensive Income (Loss), Net of Tax $10,629,534 USD -0.23%
Retained Earnings (Accumulated Deficit) $331,185,811 USD -4.1%
Stockholders' Equity Attributable to Parent $10,912,848 USD -50%
Liabilities and Equity $14,321,316 USD -47%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $3,631,163 USD 7.7%
Net Cash Provided by (Used in) Financing Activities $55,849 USD -100%
Net Cash Provided by (Used in) Investing Activities $7,978 USD
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 5,979,292 shares 10%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $13,758,982 USD -48%
Deferred Tax Assets, Valuation Allowance $50,165,532 USD 1.5%
Deferred Tax Assets, Gross $50,165,532 USD 1.5%
Payments to Acquire Property, Plant, and Equipment $7,978 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $13,063,525 USD 3.1%
Property, Plant and Equipment, Gross $153,962 USD 11%
Deferred Tax Assets, Operating Loss Carryforwards $41,058,034 USD -1.7%
Preferred Stock, Shares Authorized 40,000,000 shares 0%
Additional Paid in Capital $352,722,214 USD 0.58%
Depreciation, Depletion and Amortization $5,429 USD -12%
Share-based Payment Arrangement, Expense $100,000 USD -33%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%